Evidence map›Paper›PMID 41292880›Full record

ArticlebioRxiv : the preprint server for biology2025

Depletion and recovery of IgG following treatment with Rozanoliximab and Imlifidase in pigtail macaques.

Kara M Rzasa, Joanna Zikos, Toni Penney, Faith R Schiro, Lara A Doyle-Meyers, Pyone P Aye, Ronald S Veazey, James A Hoxie, Nicholas J Maness, Diogo M Magnani and 1 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Kara M RzasaDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA.
Joanna ZikosDepartment of Medicine, UMass Chan Medical School, Worcester, MA, USA.
Toni PenneyDepartment of Microbiology and Immunology, Tulane School of Medicine, Covington, LA, USA.
Faith R SchiroTulane National Biomedical Research Center, Tulane University, New Orleans, LA, USA.
Lara A Doyle-MeyersDepartment of Microbiology and Immunology, Tulane School of Medicine, Covington, LA, USA.
Pyone P AyeTulane National Biomedical Research Center, Tulane University, New Orleans, LA, USA.
Ronald S VeazeyTulane National Biomedical Research Center, Tulane University, New Orleans, LA, USA.
James A HoxieDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Nicholas J ManessDepartment of Microbiology and Immunology, Tulane School of Medicine, Covington, LA, USA.
Diogo M MagnaniDepartment of Medicine, UMass Chan Medical School, Worcester, MA, USA.
Margaret E AckermanDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA.ORCID 0000-0002-4253-3476

Funding

Tulane NPRC SPF Sheltered Outdoor Enclosure ExpansionP51OD011104 · OD · TULANE UNIVERSITY OF LOUISIANA · PI L Lee HAMM · 2012 to 2026
$142.4M
Structure-Function Analytics CoreP01AI162242 · NIAID · DUKE UNIVERSITY · PI TOMARAS, GEORGIA DORIS · 2021 to 2025
$22.2M
Nonhuman Primate Reagent ResourceU24AI126683 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Diogo Magnani · 2016 to 2026
$20.1M
ChimeraX -- Next Generation Visualization and Analysis Software for Multiscale ModelingR01GM129325 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2018 to 2025
$5.2M
Mechanisms and means to improve HIV bnAb activity in vivoR01AI183970 · NIAID · DARTMOUTH COLLEGE · PI Margaret E Ackerman · 2024 to 2026
$2.5M
Molecular characterization and modeling efficient antibody effector functionR01AI186995 · NIAID · DARTMOUTH COLLEGE · PI Margaret E Ackerman · 2025 to 2026
$884k
NIAID NIH HHS P01 AI162242NIAID NIH HHS R01 AI183970NIAID NIH HHS R01 AI186995NIAID NIH HHS U24 AI126683NIGMS NIH HHS R01 GM129325NIH HHS P51 OD011104
6 · The paper itself

Abstract

Antibodies are central players in adaptive immunity, providing protection against a wide array of pathogens through mechanisms such as neutralization, opsonization, recruitment of effector immune cells, complement activation and engagement. However, in other contexts, these same effector functions can contribute to immunopathology, particularly when antibodies are developed against self-antigens, resulting in autoimmunity. Understanding the role antibodies play in preventing or causing disease is often supported by studies in model systems wherein manipulation of IgG levels can be used as an experimental tool. Here, we report in simian immunodeficiency virus (SIV) infected pigtail macaques (

Indexed as

Antibody effector functionsFcRn blocking antibodyIgG DepletionIgG protease IdeSPigtail macaque

Identifiers

PMID41292880
PMCPMC12642583

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.